Verzenio (abemaciclib) carries a list price of $17,309.88 per month, which adds up to roughly $207,000 per year. That price reflects a combination of factors: the cost of developing a targeted cancer therapy, a complex manufacturing process, limited market competition, and the broader pricing dynamics of specialty oncology drugs in the United States.
What You Actually Pay Depends on Coverage
The list price is what Eli Lilly charges wholesalers, not necessarily what lands on your bill. If you have Medicare Part D, your monthly cost for Verzenio typically ranges from $0 to $14, depending on your specific plan. Private insurance copays vary more widely but are usually a fraction of the sticker price, especially if your plan has a specialty drug tier with a cap on out-of-pocket costs.
If you don’t have prescription drug coverage, or your insurer doesn’t cover Verzenio, you can expect to pay close to that full list price plus any pharmacy markup. That’s where the number becomes genuinely painful. Lilly runs a patient assistance program called Lilly Cares for people without coverage whose income falls at or below 300% of the federal poverty level (roughly $38,280 for a single person). Eligible patients can receive the drug at no cost, shipped directly to their prescriber’s office in four-month supplies.
R&D Costs and Clinical Trials
Verzenio belongs to a class of drugs called CDK4/6 inhibitors, which block specific proteins that drive the growth of hormone receptor-positive breast cancer cells. Developing a drug in this class required years of research to identify the right molecular target, synthesize a compound that hits it precisely, and then prove it works in large-scale human trials.
The pivotal MONARCH 3 trial followed patients for a median of 8.1 years, comparing Verzenio plus hormonal therapy against hormonal therapy alone in advanced breast cancer. Patients receiving Verzenio lived a median of 66.8 months compared to 53.7 months for those on hormonal therapy alone, a difference of about 13 months. For patients whose cancer had spread to organs like the liver or lungs, the gap was even larger: 63.7 months versus 48.8 months, nearly 15 additional months. Running trials of this size and duration across multiple countries costs hundreds of millions of dollars, and those costs get folded into the drug’s price during the years it remains under patent.
Verzenio is also approved for early-stage breast cancer after surgery, which required separate large trials with their own enrollment, monitoring, and regulatory review. Each new indication adds to the total development investment Lilly seeks to recoup.
Manufacturing Is Genuinely Difficult
The chemical synthesis of abemaciclib is more complicated than making a typical small-molecule drug. Published research from the development team describes a process that requires high-pressure chemical reactions, high-temperature vacuum distillations, and multiple purification steps. The drug’s key intermediate compound dissolves readily in water and common solvents, which makes isolating it from the reaction mixture challenging and leads to significant yield losses at several stages.
Unwanted side reactions create impurities that must be removed through additional crystallization steps, further reducing the amount of usable product. One side reaction alone can consume up to 15% of the material. The starting materials themselves are relatively expensive, and the process demands specialized equipment capable of handling high pressures and precise temperature control. None of this makes the $17,000 monthly price tag inevitable, but it does mean production costs per dose are meaningfully higher than for simpler drugs.
Limited Competition Keeps Prices High
Only three CDK4/6 inhibitors exist on the market: Verzenio, Ibrance (palbociclib), and Kisqali (ribociclib). When an entire drug class has just three branded options and no generics, there’s little downward pressure on pricing. All three drugs carry similar price tags. Without insurance, a supply of Kisqali runs in the same general range as Verzenio, with per-unit costs varying by dose.
Interestingly, independent cost-effectiveness analyses have found that Verzenio may not offer the best value even within this small competitive set. A Canadian drug evaluation agency concluded that, at its submitted price, Verzenio combined with another hormonal therapy was both more costly and slightly less effective than Kisqali with the same partner drug. In health economics terms, that means Verzenio was “dominated” by its competitor. Yet in the U.S. market, where drug prices aren’t set by government evaluation, these findings don’t automatically translate into lower prices. Lilly can maintain its pricing as long as insurers continue covering the drug and patients keep filling prescriptions.
The Specialty Drug Pricing System
Verzenio’s price also reflects how oncology drugs are priced in general in the United States. Cancer therapies occupy a unique position: they treat life-threatening conditions, patients and doctors have limited alternatives, and insurers face public pressure to cover them regardless of cost. This gives manufacturers significant pricing power.
The list price is also not the final number in most transactions. Lilly negotiates rebates with pharmacy benefit managers and insurers, meaning the effective price paid by the health system is lower than $17,309 per month. But those rebates are confidential, and they don’t always reach patients in the form of lower copays. The gap between the list price and what different patients actually pay can be enormous, ranging from $0 for someone on Medicare Part D to six figures annually for someone uninsured.
How to Reduce Your Out-of-Pocket Cost
If you’re facing a high bill for Verzenio, several options exist. Lilly offers a copay savings card for commercially insured patients that can reduce monthly costs significantly. The Lilly Cares patient assistance program covers uninsured patients who meet income requirements. Many cancer centers also have financial counselors who can help navigate these programs or connect you with independent foundations that provide copay assistance for breast cancer treatments.
If you have Medicare Part D, your plan likely already covers most of the cost. Starting in 2025, Medicare’s $2,000 annual cap on out-of-pocket prescription spending further limits exposure for beneficiaries on expensive cancer drugs. Checking your plan’s formulary and tier placement for Verzenio before filling the prescription can help you anticipate costs and explore whether a prior authorization or tier exception might lower your copay.